Interleukin 2, interferon-a-2a and 5-FU in metastatic colorectal cancer
1996

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer

Sample size: 44 publication Evidence: low

Author Information

Author(s): SH Goey, JW Gratama, JN Primrose, U Ward, RH Mertelsmann, B Osterwalder, J Verweij, G Stoter

Primary Institution: Rotterdam Cancer Institute (Daniel den Hoed Kliniek)

Hypothesis

The combination of IL-2, IFNa-2a, and 5-FU will improve anti-tumour activity in patients with advanced colorectal cancer.

Conclusion

The combination of IL-2 and IFNa-2a with 5-FU has only modest anti-tumour activity in advanced colorectal cancer.

Supporting Evidence

  • Six patients achieved a partial response, resulting in a 14% response rate.
  • Twenty-four patients had stable disease, and thirteen showed progressive disease.
  • The median overall survival was 47 weeks for all patients and 60 weeks for responders.

Takeaway

Doctors tested a new treatment for advanced colorectal cancer, but it didn't work much better than the usual medicine.

Methodology

This phase II study involved treating 44 patients with a combination of IL-2, IFNa-2a, and 5-FU, assessing their responses and side effects.

Potential Biases

Potential bias due to the study design and the small number of patients evaluated for response.

Limitations

The study had a small sample size and a low response rate, which may limit the generalizability of the findings.

Participant Demographics

Patients were predominantly adults under 75 years with histologically confirmed metastatic colorectal cancer.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 5-28%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication